0001209191-20-059273.txt : 20201118
0001209191-20-059273.hdr.sgml : 20201118
20201118195627
ACCESSION NUMBER: 0001209191-20-059273
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201116
FILED AS OF DATE: 20201118
DATE AS OF CHANGE: 20201118
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: LEONARD JOHN M
CENTRAL INDEX KEY: 0001563584
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37766
FILM NUMBER: 201326723
MAIL ADDRESS:
STREET 1: C/O INTELLIA THERAPEUTICS INC
STREET 2: 40 ERIE STREET, SUITE 130
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER NAME:
FORMER CONFORMED NAME: LEONARD JOHN M.
DATE OF NAME CHANGE: 20121204
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Intellia Therapeutics, Inc.
CENTRAL INDEX KEY: 0001652130
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 364785571
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 40 ERIE STREET
STREET 2: SUITE 130
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 857-285-6200
MAIL ADDRESS:
STREET 1: 40 ERIE STREET
STREET 2: SUITE 130
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-11-16
0
0001652130
Intellia Therapeutics, Inc.
NTLA
0001563584
LEONARD JOHN M
C/O INTELLIA THERAPEUTICS, INC.
40 ERIE STREET; SUITE 130
CAMBRIDGE
MA
02139
1
1
0
0
President and CEO
Common Stock
2020-11-16
4
M
0
20000
14.58
A
487352
D
Common Stock
2020-11-16
4
S
0
20000
34.00
D
467352
D
Common Stock
58415
I
By Trust
Stock Option (right to buy)
14.58
2020-11-16
4
M
0
20000
0.00
D
2028-12-17
Common Stock
20000
220000
D
The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
Shares held by the John M. Leonard 2015 Irrevocable Trust.
The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 110,000 shares as of November 16, 2020.
/s/Jose Rivera Attorney-In-Fact
2020-11-18